Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenyl[1-(n-succinylamino)pentyl]phosphonate is a synthetic small molecule phosphonate compound, structurally characterized as a transition state analog. It has been widely used in biochemical and structural studies as a hapten to elicit and study catalytic antibodies (abzymes), particularly those with esterase or amidase activity. The compound mimics the transition state of ester hydrolysis, allowing it to bind tightly to antibody active sites designed for catalysis. It is not an approved pharmaceutical drug but serves as an experimental tool in immunochemistry and enzymology research, especially for understanding antibody-catalyzed reactions and optimizing catalytic antibody affinity through phage display techniques[6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenyl[1-(n-succinylamino)pentyl]phosphonate.